Jul 12, 2022Verve Therapeutics Doses First Human with an Investigational In Vivo Base Editing Medicine, VERVE-101, as a Potential Treatment for Heterozygous Familial Hypercholesterolemia
Jun 13, 2022Verve Therapeutics Appoints Experienced Biotechnology Executive, Alexander G. “Bo” Cumbo, to its Board of Directors
May 10, 2022Verve Therapeutics Announces Clearance of First VERVE-101 Clinical Trial Application and Outlines Global Clinical Development Strategy; Reports First Quarter 2022 Financial Results
May 09, 2022Verve Therapeutics Reports Additional VERVE-101 and GalNAc-Lipid Nanoparticle Delivery Data in Non-Human Primates at TIDES USA 2022
Apr 26, 2022Verve Therapeutics Presents Comprehensive Analyses of Off-target Editing Risk for VERVE-101 at Precision Genome Engineering Keystone Symposia
Apr 04, 2022Verve Therapeutics Reports Durable and Well-Tolerated Editing of ANGPTL3 Gene Out to More than 20 Months in Non-Human Primates for Potential Treatment of Atherosclerotic Cardiovascular Disease
Mar 24, 2022Verve Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Conference
